UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...